Trevi Therapeutics Inc (TRVI)
2.73
-0.19
(-6.51%)
USD |
NASDAQ |
May 10, 16:00
Trevi Therapeutics Enterprise Value: 119.47M for May 10, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 10, 2024 | 119.47M |
| May 09, 2024 | 132.85M |
| May 08, 2024 | 113.13M |
| May 07, 2024 | 131.44M |
| May 06, 2024 | 134.26M |
| May 03, 2024 | 139.89M |
| May 02, 2024 | 139.19M |
| May 01, 2024 | 128.62M |
| April 30, 2024 | 133.55M |
| April 29, 2024 | 134.26M |
| April 26, 2024 | 122.99M |
| April 25, 2024 | 106.09M |
| April 24, 2024 | 113.83M |
| April 23, 2024 | 127.92M |
| April 22, 2024 | 134.26M |
| April 19, 2024 | 126.86M |
| April 18, 2024 | 116.30M |
| April 17, 2024 | 108.90M |
| April 16, 2024 | 114.89M |
| April 15, 2024 | 125.10M |
| April 12, 2024 | 128.54M |
| April 11, 2024 | 132.68M |
| April 10, 2024 | 115.44M |
| April 09, 2024 | 125.79M |
| April 08, 2024 | 143.37M |
| Date | Value |
|---|---|
| April 05, 2024 | 138.89M |
| April 04, 2024 | 141.30M |
| April 03, 2024 | 145.09M |
| April 02, 2024 | 149.92M |
| April 01, 2024 | 158.89M |
| March 28, 2024 | 154.94M |
| March 27, 2024 | 156.32M |
| March 26, 2024 | 150.80M |
| March 25, 2024 | 148.05M |
| March 22, 2024 | 164.60M |
| March 21, 2024 | 172.18M |
| March 20, 2024 | 161.15M |
| March 19, 2024 | 153.29M |
| March 18, 2024 | 138.95M |
| March 15, 2024 | 145.78M |
| March 14, 2024 | 130.76M |
| March 13, 2024 | 119.83M |
| March 12, 2024 | 114.37M |
| March 11, 2024 | 112.32M |
| March 08, 2024 | 110.95M |
| March 07, 2024 | 118.47M |
| March 06, 2024 | 126.66M |
| March 05, 2024 | 121.88M |
| March 04, 2024 | 117.78M |
| March 01, 2024 | 117.10M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-26.82M
Minimum
Mar 30 2020
295.06M
Maximum
Jun 03 2019
37.77M
Average
22.40M
Median
Sep 08 2020
Enterprise Value Benchmarks
| Accuray Inc | 273.70M |
| Vanda Pharmaceuticals Inc | -98.28M |
| NovaBay Pharmaceuticals Inc | 2.377M |
| Palatin Technologies Inc | 27.47M |
| iBio Inc | 16.31M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.90M |
| Total Expenses (Quarterly) | 11.91M |
| EPS Diluted (Quarterly) | -0.11 |
| Earnings Yield | -12.45% |